Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02541123 · ClinicalTrials.gov registry record
Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma
A clinical trial, sponsored by Banyan Biomarkers.
- Completed
- Registry status
- 194
- Enrollment target
NCT02541123: Completed study, sponsored by Banyan Biomarkers.
NCT02541123 is a clinical trial that has completed, run by Banyan Biomarkers. The registered enrollment target is 194 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02541123 has completed, sponsored by Banyan Biomarkers.
- COMPLETED
- Registry status
- 194 participants
- Enrollment target
Study Summary
The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale score 13-15 as well as in a group of uninjured control subjects.
Interventions
- OTHER Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 194 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-02-28 |
What the finished NCT02541123 record still lists
NCT02541123 is an observational study that tracks outcomes without assigning an intervention. The registered 194 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT02541123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02541123 about?
NCT02541123 is a clinical study titled "Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma". The primary objective of the clinical trial is to evaluate the effect of time on levels of Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) biomarker levels in a population of head injured subjects over the age of 18 presenting acutely with a Glasgow Coma Scale s...
What is the current status of trial NCT02541123?
This trial is currently completed. The enrollment target is 194 participants. The study started on 2016-01. Estimated completion is 2017-02-28.
What interventions are being tested in trial NCT02541123?
The interventions under investigation include: Blood draw (OTHER).
Who is sponsoring clinical trial NCT02541123?
This trial is sponsored by Banyan Biomarkers, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
- NCT05351424 · 194 participants · NA
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia